Epigenetic silencing of checkpoint with fork‑head associated and ring finger gene expression in esophageal cancer

Suzuki,Yoshihiro; Miyagi,Yohei; Yukawa,Norio; Rino,Yasushi; Masuda,Munetaka

doi:10.3892/ol.2013.1677

Epigenetic silencing of checkpoint with fork‑head associated and ring finger gene expression in esophageal cancer

Authors:
- Yoshihiro Suzuki
- Yohei Miyagi
- Norio Yukawa
- Yasushi Rino
- Munetaka Masuda
View Affiliations

Affiliations: Department of Surgery, Hiratsuka Kyosai Hospital, Hiratsuka, Kanagawa 254‑8502, Japan, Molecular Pathology and Genetics Division, Kanagawa Cancer Center, Yokohama, Kanagawa 241‑0815, Japan, Department of Surgery, Yokohama City University, Yokohama, Kanagawa 236‑0004, Japan
Published online on: November 11, 2013 https://doi.org/10.3892/ol.2013.1677
Pages: 69-73

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Checkpoint with fork‑head associated and ring finger (CHFR) is a mitotic checkpoint gene with tumor‑suppressor functions. Previous studies have described the hypermethylation of the CpG island in the promoter region as a key mechanism involved in silencing tumor suppressor genes. The epigenetic alterations regulating CHFR expression and the clinical significance of CHFR downregulation remain unclear. A total of 40 patients with esophageal squamous cell carcinoma who underwent primary resection were enrolled in this study. CHFR mRNA expression was quantified, followed by an evaluation of the methylation status using methylation‑specific polymerase chain reaction (MSP) techniques in 29 patients. The correlation between CHFR expression and MSP status was then analyzed. In addition, the significance of CHFR expression was determined, with respect to clinicopathological features and overall survival. Aberrant hypermethylation of the CHFR gene was observed in 13 of 29 primary esophageal cancers. The CHFR expression levels of the methylated status samples was significantly lower than that of the unmethylated status samples (P=0.014). CHFR expression levels did not exhibit clinical significance with respect to the patient characteristics or overall survival. Hypermethylation of the CHFR gene is a common event in the development of primary esophageal cancer. CpG island hypermethylation of the promoter region in the CHFR gene is a key mechanism involved in silencing the CHFR gene in patients with esophageal cancer.

View Figures

View References

1	Ding Y, Shimada Y, Kano M, et al: PTEN/MMAC1 expression in esophageal squamous cell carcinomas. Int J Oncol. 17:695–699. 2000.PubMed/NCBI
2	Roncalli M, Bosari S, Marchetti A, et al: Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. Lab Invest. 78:1049–1057. 1998.PubMed/NCBI
3	Shimada Y, Sato F, Watanabe G, et al: Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient’s prognosis and smoking history. Cancer. 89:5–11. 2000.
4	Tanaka H, Shimada Y, Harada H, et al: Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res. 58:3429–3434. 1998.
5	Privette LM and Petty EM: CHFR: A novel mitotic checkpoint protein and regulator of tumorigenesis. Transl Oncol. 1:57–64. 2008. View Article : Google Scholar : PubMed/NCBI
6	Hartwell LH and Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science. 246:629–634. 1989. View Article : Google Scholar
7	Hartwell LH and Kastan MB: Cell cycle control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
8	Scolnick DM and Halazonetis TD: Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 406:430–435. 2000. View Article : Google Scholar
9	Bertholon J, Wang Q, Falette N, et al: Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene. 22:8956–8960. 2003. View Article : Google Scholar
10	Soutto M, Peng D, Razvi M, et al: Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer. 116:4033–4042. 2010. View Article : Google Scholar : PubMed/NCBI
11	Morioka Y, Hibi K, Sakai M, et al: Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res. 26:1791–1795. 2006.PubMed/NCBI
12	Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
13	Eads CA, Lord RV, Wickramasinghe K, et al: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61:3410–3418. 2001.PubMed/NCBI
14	Nie Y, Yang G, Song Y, et al: DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis. 22:1615–1623. 2001. View Article : Google Scholar
15	Momparler RL and Bovenzi V: DNA methylation and cancer. J Cell Physiol. 183:145–154. 2000. View Article : Google Scholar
16	Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
17	Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB and Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:67–70. 1999.
18	Chaturvedi P, Sudakin V, Bobiak ML, et al: Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res. 62:1797–1801. 2002.
19	Ahel I, Ahel D, Matsusaka T, et al: Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature. 451:81–85. 2008. View Article : Google Scholar : PubMed/NCBI
20	Oh YM, Kwon YE, Kim JM, et al: Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nat Cell Biol. 11:295–302. 2009. View Article : Google Scholar : PubMed/NCBI
21	Yu X, Minter-Dykhouse K, Malureanu L, et al: Chfr is required for tumor suppression and Aurora A regulation. Nat Genet. 37:401–406. 2005. View Article : Google Scholar : PubMed/NCBI
22	Kashima L, Toyota M, Mita H, et al: CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB. Oncogene. 28:2643–2653. 2009. View Article : Google Scholar
23	Sanbhnani S and Yeong FM: CHFR: a key checkpoint component implicated in a wide range of cancers. Cell Mol Life Sci. 69:1669–1687. 2012. View Article : Google Scholar : PubMed/NCBI
24	Toyota M, Itoh F and Imai K: DNA methylation and gastrointestinal malignancies: functional consequences and clinical implications. J Gastroenterol. 35:727–734. 2000. View Article : Google Scholar
25	Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
26	Mizuno K, Osada H, Konishi H, et al: Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene. 21:2328–2333. 2002. View Article : Google Scholar : PubMed/NCBI
27	Shibata Y, Haruki N, Kuwabara Y, et al: Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 23:1695–1699. 2002. View Article : Google Scholar
28	Fang MZ, Jin Z, Wang Y, et al: Promoter hypermethylation and inactivation of O6-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol. 26:615–622. 2005.PubMed/NCBI